This is an increase of 347% compared to the typical daily volume of 1,990 put options.
Shares of Allergan plc (NYSE:AGN) opened at 238.51 on Wednesday. The company's 50-day moving average is $239.24 and its 200-day moving average is $222.20. For AGN, the company now has $1.72 Billion of cash on the books, which is offset by $2.8 Billion current liabilities.
The 52 week high of Allergan, Inc.'s shares is 261.27 whilst the 52 week low for the company's shares is 184.5.
According to Zacks brokerage recommendations, Allergan plc (NYSE:AGN)'s Buy count is 3 and Strong Buy is 9 while the number of analysts recommending Sell and Strong Sell are 0 and 2, respectively. The company provided earnings per share (EPS) guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus estimate of $16.01. The company reported $3.35 EPS for the quarter, topping the consensus estimate of $3.32 by $0.03. Allergan plc had a net margin of 100.04% and a return on equity of 7.21%. The firm's revenue was up 5.1% compared to the same quarter a year ago.
Allergan plc (NYSE:AGN) last issued its earnings results on Tuesday, May 9th.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th will be issued a $0.70 dividend.
On 5/5/2017 Allergan plc announced a quarterly dividend of $0.70 with an ex dividend date of 5/16/2017 which will be payable on 6/15/2017. This represents a $2.80 annualized dividend and a yield of 1.22%. The stock was sold at an average price of $246.68, for a total value of $17,267,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.27% of the company's stock.
The number of shares now held by investors is 335.58 Million. The analyst recommendations from a month ago are 3 Buy, 8 Strong Buy, 0 Sell, 0 Hold and 3.
The stock grew about 22.97% in the past 5 years, this positive value indicates that the stock constantly performed well in previous years as well. Apriem Advisors boosted its position in Allergan plc by 1.2% in the third quarter. The Beta factor for the stock is listed at 1.05. Enterprise Financial Services Corp raised its stake in Allergan plc by 62.7% in the first quarter. Feltz Wealth PLAN Inc. purchased a new stake in Allergan plc during the first quarter valued at about $107,000.
On 12/7/2015 Nesli Basgoz, Director, sold 2,300 with an average share price of $312.96 per share and the total transaction amounting to $719,808.00.
Several research firms recently commented on AGN. Goldman Sachs Group Inc cut Allergan plc from a "buy" rating to a "neutral" rating and set a $262.00 price target on the stock.in a research note on Wednesday. Citigroup Inc lifted their price target on Allergan plc to $261.00 and gave the stock a "buy" rating in a research report on Monday, April 24th.
The analysts offering 12 month price targets for Allergan plc have a median target of $275, with a high estimate of $400 and a low estimate of $212. Finally, Vetr upgraded Allergan plc from a "hold" rating to a "buy" rating and set a $256.33 price target for the company in a research report on Wednesday, March 1st.
Research provided by covering analysts may contain projections on where they see a certain stock going in the future.
This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Allergan plc (AGN) now trades with a market capitalization of $81.87 Billion.
COPYRIGHT VIOLATION WARNING: "Allergan plc Target of Unusually High Options Trading (AGN)" was first published by Sports Perspectives and is the property of of Sports Perspectives.